



Europäisches Patentamt
European Patent Office
Office européen des brevets



11 Publication number : 0 611 157 A2

12

EUROPEAN PATENT APPLICATION

21 Application number : 94300971.2

51 Int. Cl.⁵ : C12P 19/34, C12Q 1/68,
C07H 1/08

22 Date of filing : 10.02.94

30 Priority : 10.02.93 US 15729

72 Inventor : Kacian, Daniel L.
3911 Tambor Road
San Diego, California 92124 (US)
Inventor : Nunomura, Kiyotada
9880 Campus Point Drive
San Diego, California 92121 (US)

43 Date of publication of application :
17.08.94 Bulletin 94/33

74 Representative : Sexton, Jane Helen et al
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5LX (GB)

84 Designated Contracting States :
AT BE CH DE DK ES FR GB IT LI LU NL SE

71 Applicant : GEN-PROBE INCORPORATED
9880 Campus Point Drive
San Diego California 92121-1514 (US)

54 Method to prepare nucleic acids from a biological sample using low pH and acid protease.

57 Method for making available a desired nucleic acid contained in a biological sample, comprising the steps of acidifying said biological sample to a pH at which endogenous nucleases capable of degrading the desired nucleic acid(s) are inactive, contacting said biological sample with an exogenous acid protease active at said pH, incubating said sample until endogenous nuclease activities are reduced to insignificant levels, and raising the pH of the biological sample to a pH sufficient to render the exogenous protease less active.

Field of the Invention

5 The present invention relates to procedures for treating biological specimens to make their nucleic acids available for various purposes, such as nucleic acid hybridization assays for the diagnosis of disease and other purposes, and for amplification of nucleic acids by the polymerase chain reaction (PCR) or other target amplification procedures. Specifically, the present invention relates to convenient procedures for making nucleic acids available that prevent degradation of the nucleic acids by endogenous nucleases present in the biological sample.

10 Background of the Invention

15 Many diagnostic procedures are based on detection of specific nucleic acid (DNA or RNA) sequences present in a biological sample. For example, the sample may contain bacteria, viruses, or other microorganisms whose presence must be ascertained to determine the cause of an infectious disease. In other instances, the nucleic acid sequence may be sought within the DNA of a human white blood cell in order to establish the presence of a mutation associated with cancer or a genetic disease.

20 For such a diagnostic analyses, it is necessary to make available the specific nucleic acid that may be present in the sample. Frequently, the nucleic acid will be contained within a bacterium, fungus, virus, or other microorganism or within human cells such as white blood cells. It may further be contained within other structures such as ribosomes, plasmids, or chromosomal DNA. In order to perform hybridization reactions to detect specific nucleic acids or to amplify them using PCR or other target amplification methods, the nucleic acid must be released from these organisms and/or structures.

25 Unfortunately, such release exposes the nucleic acids to degradation by endogenous nucleases present in the sample, which may exist in such abundance that the nucleic acid is almost instantaneously destroyed.

30 The problem is particularly acute when the specific nucleic acid is an RNA, since RNases are abundant in most biological samples and are often extremely resistant to treatments that readily inactivate many other enzymes.

35 To deal with this problem, it is common in the art to employ a variety of means to purify the nucleic acids from the biological sample. For example, anionic detergents and chaotropic agents such as guanidinium salts have been used to simultaneously inactivate or inhibit nuclease activities and release nucleic acids from within cells and subcellular structures. Unfortunately, these agents are also potent inhibitors of the enzymes used in target amplification processes or in many hybridization detection methods or, in the case of chaotropes, may interfere with hybridization itself. Therefore, it has been necessary to use additional steps to remove these agents and recover the nucleic acids.

40 The most commonly used procedure is to precipitate the nucleic acids from the sample using various salts and ethanol. The sample must be kept at reduced temperature (usually -20°C or lower) for some hours and centrifuged at high speed in order to achieve good yields of nucleic acids in most instances.

45 Because other macromolecules also precipitate under these conditions producing a sticky, intractable mass that entraps the nucleic acids, it has been frequently necessary to resort to extraction of the sample with hazardous organic solvent mixtures containing phenol, cresol, and/or chloroform prior to ethanol precipitation. In some cases when anionic detergents are used, proteases that are active in the presence of these detergents, such as proteinase K or pronase, are used to partially degrade protein components of the sample to minimize entrapment during organic solvent extraction, and/or degrade components that may not be extracted by the solvent treatment.

50 It will be readily appreciated that these methods are complex, tedious, labor-intensive, and slow. If great care is not taken in performing the procedure, residual contamination with nucleases can occur, and the sample nucleic acids will be degraded or lost. Diagnostic tests performed with such samples may give false negative results. False negative results can also be obtained if residual anionic detergents, chaotropic salts, or ethanol remain in the sample and inhibit hybridization and/or target amplification procedures. If anionic detergents and proteases have been used, residual proteolytic activity can also degrade the enzymes used in target amplification and/or hybridization detection reactions and produce false negative results. On the other hand, improper processing with these methods can also result in the isolation of denatured proteins or other macromolecules that can entrap labelled probes and produce false positive results with diagnostic tests involving nucleic acid hybridization. Thus, these procedures are not well suited for routine processing of biological specimens received in clinical laboratories in any quantity.

55 Particularly, trouble is encountered with many biological samples in which the desired nucleic acid species is RNA, and the sample contains significant amounts of RNase of the "pancreatic" type (also frequently referred to as "ribonuclease A"). Pancreatic RNases are present in serum and plasma and in many tissues of

the body. They are resistant to denaturation by heat and acids and will even withstand boiling in 1 N HCl for 10 minutes without loss of activity. They are inhibited by anionic detergents, chaotropes, and organic solvents such as phenol, but are not irreversibly inactivated by these agents; therefore, when the detergents, chaotropes, or solvents are removed, the RNase (if not eliminated by careful extraction) can proceed to degrade 5 the desired RNA.

Exposure to strong alkali will irreversibly inactivate these RNases; however, such conditions also result in the degradation of RNA itself.

The present invention addresses these problems by providing a method for conveniently inhibiting and 10 inactivating nucleases in biological samples while making available sample nucleic acids for hybridization assays, target amplification procedures, or other uses. Inhibitory detergents or chaotropes are not required in the sample, and there is no residual proteolytic activity. The method is simple and applicable to processing large numbers of samples simultaneously. Unlike ethanol precipitation methods, it does not use hazardous 15 organic solvents, nor require equipment for cooling the sample or recovering precipitates by centrifugation.

15 Summary of the Invention

The present invention features a procedure for irreversibly inactivating endogenous nucleases in biological samples by reducing the pH below that at which the endogenous nucleases present in the sample are active, adding a protease which is active at that pH and which degrades any nucleases that have not been irreversibly inactivated by exposure to low pH, and then inactivating the protease (after it has done its work) by 20 raising the pH. At the higher pH, the chosen protease is either inactive or is irreversibly inactivated. If possible, the protease is chosen so as to aid in the digestion of other macromolecules in the sample that may interfere with the intended use of the sample, and chosen to help make available the desired nucleic acids by degrading microorganism cell walls, virus particles, ribosomes, and/or other structures containing the desired nucleic acids. Alternatively, solubilization of these structures and release of the nucleic acids may be effected by the 25 use of detergents, heat, or other means once sample nuclease activity has been effectively controlled, reduced, or eliminated.

In general, the biological sample is adjusted to a low pH where the endogenous nucleases are either irreversibly inactivated or are effectively inhibited. Exogenous acid protease (such as pepsin) is then added or 30 may be added simultaneously with the pH lowering solution. The action of the acid protease digests the endogenous nucleases present in the sample and irreversibly inactivates them so that they will not degrade the sample nucleic acids when the pH is subsequently raised. In addition, the protease will usually act to liberate the nucleic acids from microorganisms, human cells, or subcellular components such as ribosomes and nuclei. It will also degrade many protein components of the biological sample, including ones that may interfere with 35 subsequent use of the sample for hybridization assays and/or target amplification procedures.

The acid protease selected should have activity at an acidic pH, pH 1.0 to pH 4.0, and be able to digest a wide variety of proteins, including the nucleases found in the sample as well as other unwanted components. In addition, it should ideally be able to digest components which contain the desired nucleic acid. In some cases, it may be desirable to select a protease of more limited specificity in order that a nucleic acid (whose presence in free form in the sample is undesirable) is not liberated from its component structures. 40

The acid protease should also be checked to ensure that it is itself free of nuclease activities that are active at the chosen acidic pH or which are resistant to degradation and inactivation by the chosen acidic protease.

Commercial preparations of acid proteases may be contaminated with such enzymes and should be purified, if necessary, to eliminate them. In the examples that follow, a procedure for purifying commercially available pepsin preparations to eliminate residual RNase activities that are not eliminated by pepsin digestion is given. Equivalent procedures can be used for other proteases. 45

The protease is rendered inactive by the simple act of raising the pH. With some acid proteases, this is sufficient to completely stop further proteolytic digestions and may irreversibly denature and inactivate the enzyme. With other proteases, it may be necessary to resort to heating the sample to achieve complete inactivation of the protease. Since the nucleases have been destroyed and nucleic acids are not damaged by brief 50 exposure to heat at neutral pH, they will survive this procedure intact.

Accordingly, this invention provides a simple procedure to extract nucleic acids *in vitro*. This procedure can be used for processing many biological samples, including those containing viruses, such as hepatitis C virus, which presents particular difficulties because it is an RNA-containing virus which is difficult to open, 55 the sample is serum or plasma which contains significant amounts of pancreatic-type RNase activity, and the virus is often present in very low amounts which makes recovery of the nucleic acids by ethanol precipitation techniques difficult.

Thus, in a first aspect, the invention features a method for purifying or making available a nucleic acid

from a biological sample by acidifying the biological sample to a pH at which endogenous nucleases (capable of degrading the desired nucleic acids) are less active, *e.g.*, to a pH between 1.0 and 4.0; contacting the biological sample with an exogenous acid protease active at that pH; incubating the sample until endogenous nucleases have been degraded to insignificant levels (*i.e.*, to a level where their effect on levels of nucleic acids in the sample is insignificant, *e.g.*, at a level where less than 5% of the nucleic acids are degraded over a period of 60 minutes at 37°C in a standard salt solution); and raising the pH of the biological sample with a base to a pH sufficient to render the exogenous protease less active, *e.g.*, to a pH at which the protease is no longer active.

By "making available" is meant that the nucleic acid is accessible for later analyses, such as hybridization or amplification.

By "less active" is meant, with respect to endogenous nucleases, is less nuclease activity than prior to treatment (under the same conditions). By "less active" is meant, with respect to exogenous proteases, is less protease activity than prior to treatment. Preferably, the lower exogenous protease activity is insufficient to reduce the activity of enzymes used in later processes involving the isolated nucleic acids.

By "degraded" is meant that the activity of the nucleases is reduced to a level which will allow later experiments or manipulations of the isolated nucleic acids.

By "desired nucleic acid" is meant a nucleic acid that is obtained, possibly along with other nucleic acids by this invention, and can subsequently be specifically identified.

In preferred embodiments, a biological sample is chosen from tissue cells, blood components, and other human biological materials which may contain infectious disease agents; the biological sample consists of human white blood cells, cancer cells, or other cells which offer a convenient source of human cellular nucleic acid for genetic analysis, body fluids, secretions, or tissues; the "acid protease" is pepsin; the pH of the sample after incubating, preferably at pH 4 or lower in the presence of exogenous protease, is raised up to a level suitable for subsequent use, but below that level at which the exogenous protease is completely inhibited or inactivated; in the acidifying step the pH is adjusted to between 1.0 and 4.0; in the raising step the pH is adjusted to be greater than 6.0; following the raising step the sample is heated to aid inactivation of the acidic protease and/or other enzyme activities present in the sample; detergents are added to the sample to aid release of the desired nucleic acid from other sample components; and the time of the incubating is longer than necessary to reduce endogenous nuclease levels to insignificant levels, in order to effect lysis of sample components and/or degradation of other sample components.

In related aspects, the invention features a kit including components necessary to carry out the method of this invention, and a method for purifying pepsin from RNases for use in this method. Such purification makes use of an RNase adsorbent which does not adsorb proteases, *e.g.*, Macaloid or bentonite. Macaloid is a natural clay mineral product that has the property of adsorbing RNases to its surface. Bentonite is a similar material which is a colloidal native hydrated aluminum silicate clay consisting primarily of montmorillonite. Both can often be used interchangeably to remove RNases from a variety of biological materials. Other more-or-less specific adsorbents could be used provided they adsorb the RNases and not the desired protease.

Description of the Preferred Embodiments

The present invention provides a procedure for isolating nucleic acids from different types of biological samples under acidic conditions where the degradation of these nucleic acids is minimized. This process is particularly useful for obtaining nucleic acids from specimens where there is a risk of significant degradation of nucleic acids by endogenous nucleases. Nucleic acids which can be isolated by this procedure include naturally occurring nucleic acids and synthetic nucleic acids or oligonucleotides.

The biological samples containing the nucleic acids to be isolated include tissue cells, blood components, viruses, microorganisms, pathogenic organisms, and body fluids containing these various organisms.

An initial step of the procedure of the present invention is adjustment of the acidity of the biological specimen containing the desired nucleic acids to about pH 4 or lower. At this pH, nucleases which may be present in the biological sample are not active. KCl-HCl buffer, glycine-HCl buffer, acetic acid buffer and various other acidic buffer compositions having buffering activity in acidic conditions, can be used to reduce the pH of the specimen. Endogenous nucleases present in clinical samples do not work (*i.e.*, have negligible enzymatic activity) at a sufficiently acidic pH, since this pH is far below their optimum range. For example, serum RNase has its optimum pH at about 6.5. It has almost no activity at pH 3.0 or lower. Leukocyte RNase has an optimum pH range from 6.0 to 6.5 and has virtually no enzymatic activity at pH 4.0 or lower. Therefore, the adjustment of acidity of the mixture to about pH 4 or lower will prevent the action of most known endogenous RNases.

Similarly, serum deoxyribonuclease activity has its optimum pH at about 5.8 to 7.0, depending upon the type of divalent metal(s) present. It shows little activity below pH 5.0, regardless of metal ion present. Leukocyte

DNAse has an optimum pH range from about 4.0 to about 5.0, and it is virtually inactive below pH 3.0. The exact pH ranges at which nucleases found in clinical samples are active will depend upon such variables as the type of buffer used to control the pH, metal ion requirements, if any, and temperature.

For use of the present invention, those skilled in the art know how to assay for activities that degrade one or more nucleic acids of interest, and can easily determine the appropriate pH, buffer, and temperature that is needed for a particular sample type. In particular, it may be important to lower the temperature and minimize the time of exposure to very low pH when it is desired to recover DNA, since depurination of the DNA can occur at low pH when higher temperatures and longer times are employed. However, it is an important feature of the present invention that some DNA depurination and chain breakage may occur and is useful in that it helps to break up gelatinous aggregations of DNA that are produced when some biological specimens (for example, white blood cell pellets) are lysed. Thus, the present invention can address this additional specimen processing problem as an added benefit of the method.

The next step (which can be performed simultaneously, or even before, the first step if desired) is addition of an acidic protease into the acidified biological samples. The endogenous nucleases in the reaction mixture are digested and irreversibly inactivated by this protease. In this step, the desired nucleic acids may also be liberated from the biological sample into the aqueous solution when the biological components, e.g., cell membranes, are also digested by the acidic protease. Pepsin is one example of an acidic protease which can be used in this step. Other proteases can be used as long as they retain enzymatic activities under acidic conditions that inactivate the unwanted nuclease activities present in the biological sample. Such proteases are readily identified by those in the art using standard procedures.

Nucleic acids released by the steps described above are stable because the aqueous solution no longer contains active nuclease (even after neutralization of the solution to inactivate the acidic protease by addition of alkali). Such neutralization provides physiological conditions suitable for subsequent enzymatic reactions, e.g., for nucleic acid amplification procedures such as PCR, and cDNA polymerization methods. Thus, the neutralized solution may be used directly in such procedures without further processing, e.g., without removal of strong anionic detergents or other harsh agents which may affect the activity of enzymes used in subsequent processes.

This procedure provides significant advantages over other nucleic acid isolation methods, since no process is required to remove guanidine isothiocyanate or other denaturing agents (used in other procedures). The exogenous acid protease inactivates endogenous nucleases irreversibly and liberates nucleic acids from the biological sample in one step. This procedure may be readily and simply used to isolate nucleic acids from a biological sample for genetic diagnosis and thus is useful in a clinical laboratory.

The following examples are set forth to illustrate various aspects of the present invention, but do not limit in any way its scope as more particularly set forth in the claims.

Example 1: Inhibition of Human Serum RNases at Low pH

A human blood sample was taken from a healthy volunteer. The blood was allowed to stand at room temperature (about 20°C) to coagulate. The blood clot was removed by low speed centrifugation. The serum obtained was used as the source of human serum RNase.

Serum RNase activity was studied by the following procedure. KCl was added to 5 microliters of serum to a final concentration of 50 mM. HCl was added to a final concentration in a range from 20 mM to 97 mM. RNA was added as substrate of RNase. The volume was adjusted to 10 microliters. The acidity of the solution varied from pH 1.5 to pH 5.0 depending on the amount of HCl included in the solution. The solution was incubated at 37°C for 20 minutes to allow degradation of the RNA by the serum RNase.

The amount of RNA remaining was determined by a chemiluminescent labeled-probe hybridization assay as described in Arnold et al., EP 309230. Briefly, the reaction mixture was denatured by heating at 95°C upon completing the reaction. A solution containing a chemiluminescent labeled probe (complementary to the RNA in the mixture above) was added and the resulting mixture was incubated at 60°C for 20 minutes. A reagent was added to selectively inactivate the chemiluminescent label of the unhybridized probe and incubated at 60°C for 4 minutes. After cooling to room temperature, the chemiluminescence of the hybridized probe was measured in relative light units (RLU) using a luminometer.

About 50% of RNA added to the reaction solution was recovered after treatment at pH 4.0. One hundred percent of RNA added was recovered at pH 3.5 or lower. RNase activity of the serum was significantly reduced at about pH 4.0 or lower, and its enzymatic activity was completely lost at pH 3.5 or lower. These results are illustrated in Table 1.

5
10
15
20
25
30
35
40
45
50
55

TABLE 1

pH	HCl conc. (mM)	RLU raw		*RLU net		**%RLU Recovery
		Non Serum	With 5uL Serum	Non Serum	With 5uL Serum	
1.5	97	12762	15341	12042	13665	113.5
1.5-2	86	16721	15346	16001	13670	85.4
2	75	13440	14701	12720	13025	102.4
Test	2-2.5	64	11907	13911	11187	12235
	3	53	14198	14638	13478	12962
	3.5	42	15124	14814	14404	13138
	4-4.5	33	16011	6698	15291	5022
	5	20	16317	2211	15597	535
Controls						
Non RNA	1.5	97	720	1676	0	0

*RLU net: The RLU's of reactions without target RNA (background) were 720 RLU and 1676 RLU in Non Serum and With Serum reactions respectively.

"RLU net" indicates the raw RLU values minus background RLU values.

** % RLU Recovery:

RLU value of With Serum reaction/RLU value of Non Serum reaction X 100

Example 2: Human Leukocyte RNase

The blood of a healthy volunteer was treated with saponin to dissolve erythrocytes. The leukocytes were collected by low speed centrifugation. The leukocytes were then washed with physiological saline and dissolved in a buffer containing Triton X-100. The resulting solution was used as the human leukocyte RNase solution.

The pH dependency of human leukocyte RNase was then studied by a procedure similar to that in Example 1. Briefly, the RNase solution was added to 40 mM potassium acetate pH 4.0 buffer containing 12.25 mM NaCl and 10 mM MgCl₂. RNA was added to the solution and the total volume brought up to 10 microliters. The reaction solution was incubated at 37°C for 20 minutes to digest the RNA with the human leukocyte RNase. Upon completing the reaction, the amount of RNA remaining was determined by the labeled-probe hybridization assay described in Example 1.

As a control, 30 ml of Tris-HCl buffer (pH 7.7) was used instead of potassium acetate buffer to prepare the reaction mixture. Human leukocyte RNase solution, prepared from 5 microliters of blood, was added and a reaction procedure similar to that described above was carried out. In the reaction mixture buffered at pH 7.7, the added RNA was digested to a non-detectable level by the leukocyte RNase obtained from the 5 microliters of human blood under these conditions. In contrast, about 85% of the original RNA was recovered when human leukocyte RNase solution from 100 microliters of blood was added to a reaction mixture at pH 4.0. Thus, human leukocyte RNase activity is substantially reduced at pH 4.0. The results of two sets of tests are shown in Table 2.

25

30

35

40

45

50

55

5

10

15

20

25

30

35

40

45

50

55

TABLE 2

Test 1

	pH	Buffering Agent	* Volume of Blood	RLU raw	**RLU net	***%RLU Recovery
Test	7.7	20mM TrisCl	0	14655	14108	100
	7.7	20mM TrisCl	0.06	10885	10338	73.3
	7.7	20mM TrisCl	0.2	5403	4856	34.4
	7.7	20mM TrisCl	0.6	1466	919	6.5
	7.7	20mM TrisCl	1.7	981	434	3.1
	7.7	20mM TrisCl	5	1461	914	6.5
	4	40mM K.Acetate	0	11574	11000	100
Test	4	40mM K.Acetate	0.06	11396	10822	98.4
	4	40mM K.Acetate	0.2	10797	10223	92.9
	4	40mM K.Acetate	0.6	11481	10907	99.2
	4	40mM K.Acetate	1.7	10407	9833	89.4
	4	40mM K.Acetate	5	11470	10896	99.1
Controls						
Non RNA	7.7	20mM TrisCl	0	547	0	0
Non RNA	4	40mM Na.Acetate	0	574	0	0

Non RNA
Non RNA

*Volume of blood WBC lysate:

Volume of blood from which WBC RNase preparation was obtained.
**RLU net:

"RLU net" indicates the RLU values subtracted with the background RLUs from raw values
(Background is the RLU value of reactions where Non RNA is present.)

***%RLU Recovery:
% of RLU against RLU value of Non WBC lysate reaction

5
55 50 45 40 35 30 25 20 15 10

TABLE 2 (Cont'd)

Test 2

	pH	Buffering Agent	* Volume of Blood	RLU raw	**RLU net	***%RLU Recovery
Test	7.7	20mM TrisCl	0	19694	19057	100
	7.7	20mM TrisCl	0.06	15407	14770	77.5
	7.7	20mM TrisCl	0.2	5986	5349	28.1
	7.7	20mM TrisCl	0.6	1040	403	2.1
	7.7	20mM TrisCl	1.7	948	311	1.6
	7.7	20mM TrisCl	5	694	57	0.3
	4	40mM K.Acetate	0	15195	14566	100
	4	40mM K.Acetate	1.3	13429	12800	87.9
	4	40mM K.Acetate	4	14195	13566	93.1
	4	40mM K.Acetate	11.9	14712	14083	96.7
Controls						
Non RNA	7.7	20mM TrisCl	0	637	0	0
Non RNA	4	40mM Na.Acetate	0	629	0	0

*Volume of blood WBC lysate:

¹Volume of blood from which WBC RNase preparation was obtained.

*+RLU net:

"RLU net" indicates the RLU values subtracted with the background RLUs from raw values
(Background is the RLU value of reactions where Non RNA is present.)

***%RLU Recovery:

% of RLU against RLU value of Non WBC lysate reaction

Example 3: Recovery of Added RNA

Serum from healthy volunteers was isolated by a conventional procedure. KCl, NaCl and MgCl₂ was added to a final concentration of 50 mM, 86 mM, 10 mM and 25 mM, respectively, to 5 microliters serum. The acidity of the solution was adjusted to pH 2.5 - 1.0 to inactivate RNases in the mixture. RNA was added as a substrate, and the volume brought up to 10 microliters with water. Pepsin was then added to a final amount of between 2.5 and 200 units. This mixture was incubated at 37°C for 5 minutes. Upon completion of the reaction, Tris base was added to the reaction mixture to a final concentration of 50 mM, and the volume of the mixture brought up to 20 microliters. This base neutralizes the acidity of the mixture and adjusts the pH to about 7.0. The mixture was incubated at 37°C for an additional 20 minutes. Upon completing the reaction, RNA remaining in the mixture was denatured by heating at 95°C, and a labelled probe (complementary to the RNA in the above mixture) was added. The mixture was incubated at 60°C for 20 minutes and assayed for any remaining RNA performed as above.

One hundred percent of the exogenous RNA was recovered under these conditions in the presence of pepsin at 2.5 units or more. This example demonstrates that serum RNase is irreversibly inactivated by pepsin, and that exogenous RNA in the reaction mixture can be recovered without being affected by serum nucleases. These results are shown in Table 3.

20

25

30

35

40

45

50

55

10.

Table 3

	Pepsin (U/10 μ l)	Serum (μ l/10 μ l)	Reaction)	Reaction)	RLU raw	*RLU net	**%RLU Recovery
Tests	0	5			1816	69	0.1
	2.5	5			85595	83848	14.7
	5	5			84773	83026	14.5
	10	5			72493	70746	12.4
	25	5			92796	91049	16.0
	50	5			92204	90457	15.8
	100	5			86124	84377	14.8
	200	5			80382	78635	13.8
Controls							
Non RNA	0	0			1747	0	0
Non Serum	0	0			58822	57075	100

* RLU net: The background RLU was 1747. RLU net = RLU raw - 1747
 ** % RLU Recovery: The total RLU net was 57075. % RLU Recovery = RLU net/57075 x 100

Example 4: HCV Test Sample

55

The procedure of the present invention was evaluated by using a sample serum including hepatitis C virus. The sample serum used was obtained from a hepatitis C infected patient, confirmed to be hepatitis C virus positive by a commercial hepatitis C antibody detection kit.

In order to confirm the recovery of hepatitis C viral RNA without degradation by endogenous serum RNAses, the trace amount of RNA present in such a sample must be amplified after extraction from the sample. In this example, the RNA target is used to form a DNA target by a procedure which amplifies the nucleic acids using reverse transcriptase. The DNA product obtained is then amplified twice by a PCR procedure. Random primers were used in the reverse transcription reaction, and two primers were used in each PCR procedure. This procedure is provided in detail below.

5 Five microliters of HCV positive serum were taken and 5 microliters HCl buffer (86 mM HCl, 50 mM KCl, 10 mM MgCl₂, and 25 mM NaCl) were added. 25 units of pepsin (Macaloid treated) were then added. The mixture was incubated at 37°C for 15 minutes. The HCV sample was neutralized to pH 7.0 by addition of 5 µl of 172 mM KOH solution. The mixture was heated to 95°C for 2 minutes, and cooled to room temperature (about 10 20°C), 75 µl of reaction premix containing 0.5 microgram (250 pmol) of random primers (TaKaRa, Japan), 13.3 mM Tris-HCl (pH 8.3), 0.7 mM MgCl₂, and 0.27 mM each of dATP, dTTP, dGTP, and dCTP (Pharmacia) were 15 then added and the total volume brought up to 90 microliters. The mixture was heated to 65°C for 5 minutes and cooled to room temperature. 1 µl containing 200 units/µl of MMLV reverse transcriptase (BRL) was added to the reaction mixture, and the mixture incubated at 37°C for 30 minutes. PCR reactions were performed in accordance with the conditions specified in Mullis, U.S. Patent 4,683,195. Briefly, upon completing the reverse 20 transcription reaction, 100 pmol of two primers was added which correspond to the NS5 region of HCV. 2.5 units of Taq DNA polymerase were added and the total volume brought up to 100 µl. The reaction products were denatured by heating for 2 minutes at 92°C. A cycle of heating and cooling was repeated 40 times. (Each 25 cycle includes heating at 92°C for 1.5 minutes, heating at 53°C for 1.5 minutes, and heating at 70°C for 2 minutes). The resulting mixture was then incubated at 70°C for 9 minutes.

A 10 microliter aliquot of the mixture was then mixed with a secondary primer set designed to hybridize in a location within the primary primer set used in the primary PCR reaction. (The actual Primers used in these 25 examples are not essential in this invention.) The volume of the mixture was brought up to 100 microliters, and the secondary PCR reaction performed under the same conditions used in the primary PCR reaction. (Specifically, 10 mM Tris-HCl, pH 8.3, 100 pmol primers, 1.5 mM MgCl₂, 50 mM KCl, 0.2 mM each dNTP, and 2.5 units of Taq polymerase were used.)

The nucleic acids obtained from these amplifications were denatured by heating at 95°C for 5 minutes. 30 90 µl labelled probe was added to assay for nucleic acids using the method described in Example 1. The results are summarized in Table 4.

TABLE 4

Serum Specimen	RLU Observed
Healthy	686
Patient PI	10027
Patient POM	6553
Patient POT	5422

These data indicate that the strength of the signals of an HCV positive serum is 8 to 15 times greater than 45 that of a healthy serum. Thus, HCV RNA was liberated by the procedure without being affected by endogenous RNAses. This example also demonstrates that the RNA isolated by the methods of this invention can be used as a substrate for enzymatic reactions without any other purification or isolation process. Accordingly, it is expected that the methods of the present invention can be widely used by themselves, or in combination with other amplification procedures in order to detect specific nucleic acids in diagnostic tests.

50 Example 5: HCV Test Sample. Non-PCR Amplification

The following is another protocol for detection of nucleic acid in an HCV sample. 5 µl of pepsin solution in buffer (KCl/HCl or Glycine/HCl) is placed into appropriate tubes (pepsin was obtained from Sigma). The pepsin solution for KCl/HCl buffer contains 25 U pepsin in 100 mM KCl-172 mM HCl; and for Glycine/HCl buffer contains 55 25 U pepsin in 400 mM Glycine-400 mM HCl.

5 µl of serum specimen (healthy or HCV infected patient) was added to these tubes, and incubated at 37°C for 15 minutes.

10 µl of neutralization solution was added (neutralization solution for KCl/HCl buffer is 172 mM KOH-128

5 mM KCl; and for Glycine/HCl buffer was 200 mM KOH). The sample was then amplified essentially as described by Kacian and Fultz, NUCLEIC ACID SEQUENCE AMPLIFICATION METHODS UTILIZING A TRANSCRIPTION COMPLEX, PCT/US90/03907. This mixture was incubated at 37°C for 4 hours, and 10 µl of amplified samples subject to HPA using AE-CP-6278 probe (NS5 region). The results are shown in Table 5.

10 TABLE 5

	Serum Specimen	RLU Observed	
		KCl/HCl Buffer	Glycine/HCl Buffer
10	Healthy	3541	1127
15	Patient PKB	15165	1421
15	Patient PN-1	101146	82361
20	Patient PT-1	166160	1051277
20	Patient PH-1	802740	907997
25	Patient PY-2	1143597	1126462
25	Patient P- 7	1143699	1147653
25	Patient P-37	407889	471565
25	Patient P-27	1089869	1113446
25	Patient P-32	512470	516870
25	Patient P-37	314846	579284
30	Patient P-38	948738	756643

These results show that HCV can be detected using a non-PCR amplification system in conjunction with the present invention.

Example 6: Procedure for Purifying Pepsin with Macaloid

35 The following is a procedure for preparing pepsin free of potentially harmful enzyme activities.

A. Preparation of stock solution of Macaloid suspension (16 mg/ml): (This procedure is the same as that described in Molecular Cloning 1St Edition (Maniatis et al., 1982, p452)).

1. Weigh 0.25 g of Macaloid.
2. Suspend 0.25 g of Macaloid in 25 ml of 50 mM Tris-HCl pH 7.5.
3. Boil the suspension at 100°C for 5 minutes with constant agitation.
4. Centrifuge the Macaloid suspension at 2500xg at 4°C.
5. Discard the supernatant.
6. Re-suspend the pellet in 20 ml of 50 mM Tris-HCl pH 7.5.
7. Centrifuge the Macaloid suspension at 2500xg at 4°C.
- 40 8. Repeat the procedure 5 through 7 (washing procedure) 4 more times.
9. Re-suspend the sticky pellet in 15 ml of 50 mM Tris-HCl pH 7.5.
10. Store the Macaloid suspension at 4°C or -20°C.

B. Preparation of working Macaloid suspension for adsorption of contaminated RNase in pepsin:

50 Pepsin is readily inactivated at neutral pH. Therefore the buffer suspending Macaloid should be substituted with buffer of acidic pH to use in pepsin preparation.

1. Place Macaloid suspension in 50 mM Tris-HCl into EPPENDORF tube.
2. Centrifuge the Macaloid suspension at 5000 rpm in microfuge (5 minutes)
3. Discard the supernatant.
4. Add 150 mM NaCl-10 mM sodium acetate buffer pH 5.2.
5. Stand the Macaloid suspension at 4°C for several hours.
- 55 6. Centrifuge the tube at 5000 rpm in microfuge (5 minutes).
7. Discard the supernatant.

8. Repeat procedure 4 through 7 until the pH of Macaloid suspension is below 5.5. (Typically this takes four or five repeats of buffer substitution.)

9. Re-suspend the Macaloid in 150 mM NaCl-10 mM sodium acetate buffer pH 5.2 (same volume as starting volume).

5 C. Adsorption of contaminated RNase in pepsin to Macaloid:

1. Dissolve pepsin (Sigma Cat#6887) in 10 mM HCl-50% Glycerol to 345 U/ μ l.
2. Place 150 μ l of pepsin in EPENDORF tube.
3. Add 50 μ l of Macaloid suspension in 150 mM NaCl-10 mM sodium acetate buffer pH 5.2 and mix.
4. Keep the tube in ice-water for 2 hours.
- 10 5. Centrifuge the tube at 7500 rpm in microfuge for 10 minutes at 4°C.
6. Transfer 150 μ l of supernatant to another tube. (The pH of the supernatant is around 4.5.)
7. Add another 50 μ l of Macaloid suspension in step 3 and mix.
8. Keep the tube at 4°C for 15 minutes.
9. Centrifuge the tube at 7500 rpm in microfuge for 10 minutes at 4°C.
- 15 10. Transfer 150 μ l of supernatant to another tube. (The pH of the supernatant is around 4.5.)
11. Add 50 μ l of Macaloid suspension in step 3 and mix.
12. Keep the tube at 4°C for 15 minutes.
13. Centrifuge the tube at 7500 rpm in microfuge (10 minutes).
14. Take the supernatant into another tube and keep it at -20°C. (The pH of the supernatant is 4.5 - 20 5.0 (close to 4.5))

D. Assay for pepsin activity:

Pepsin activity after adsorption procedure to Macaloid was tested by standard procedure after each adsorption step. The results are shown in Table 6.

TABLE 6

Pepsin (Unit equivalent/Rxn)	A 520nm			
	Original soln	1st Adsorption	2nd Adsorption	3rd Adsorption
0	0.12	0.12	0.12	0.12
10	0.32	0.36	0.46	0.44
40	1.37	1.03	1.02	1.20
70	1.91	1.78	1.69	1.77
100	2.23	1.74	2.26	2.16

40 The pepsin activity after adsorption is calibrated using the standard curve drawn from the original pepsin solution.

This data shows that pepsin activity was not affected by Macaloid adsorption procedure.

E. Assay for contaminating RNase activity in pepsin:

45 Contaminating RNase activities in pepsin were measured by monitoring loss of ability of an acridinium ester-labelled DNA probe to hybridize to an RNA substrate. The RNA used was an *in vitro* synthesized transcript of sequences found in a portion of the ribosomal RNA of *Chlamydia trachomatis*. Contaminating RNase activities in both original pepsin solution (non-adsorption) and pepsin preparation after the third adsorption were tested.

50 The reactions were set up so that each reaction tube contained the amount of RNA transcript which, when annealed with the DNA probe, produced 40,000 relative light units (RLU) signal in the absence of RNase, 50 mM Tris-HCl (pH 7.5), 10 mM MgCl₂, 25 mM NaCl, and 2% Glycerol. 0 U, 345 U or 690 Units equivalent of a pepsin preparation were added. The total volume was 20 μ l. Negligible or non-detectable amounts of RNase activity was detectable after Macaloid treatment of the pepsin.

55 The present disclosure and patent applications cited in this specification show the technical levels of those skilled in the art. It will be apparent to those skilled in the art, that various changes, modifications, and variations may be made without departing from the spirit and scope of the invention as defined by the present claims.

Other embodiments are within the following claims.

Claims

1. A method for making available a desired nucleic acid contained in a biological sample, comprising the steps of:
 - 5 acidifying said biological sample to a pH at which endogenous nucleases capable of degrading the desired nucleic acid(s) are inactive,
 - contacting said biological sample with an exogenous acid protease active at said pH,
 - incubating said biological sample until endogenous nuclease activities are reduced to significant levels, and
 - 10 raising the pH of said biological sample to a pH sufficient to render said exogenous protease less active.
2. The method of claim 1, wherein said biological sample is a human biological material which may contain an infectious disease agent.
- 15 3. The method of claim 2, wherein said human biological material is either a tissue cell, or a blood component.
4. The method of claim 1, wherein said biological sample is a cell containing human cellular nucleic acid.
5. The method of claim 4, wherein said cell is either a human white blood cell or a cancer cell.
- 20 6. The method of claim 1, wherein said biological sample is human serum.
7. The method of any one of the preceding claims wherein said acid protease is pepsin.
8. The method of any one of the preceding claims in which the pH of the sample after said incubating is raised only to a level suitable for subsequent use but not to a level at which the exogenous protease is completely inhibited or inactivated.
- 25 9. The method of any one of the preceding claims wherein in said acidifying step the pH is adjusted to be between 1.0 and 4.0.
10. The method of any one of the preceding claims wherein in said raising step the pH is adjusted to be greater than 6.0.
- 30 11. The method of any one of the preceding claims wherein following said raising step inactivation of the acidic protease is aided by heating said sample.
12. The method of any one of the preceding claims wherein a detergent is added to the sample to aid release of the desired nucleic acid from other sample components.
- 40 13. The method of any one of the preceding claims wherein the time of said incubating is longer than necessary to reduce endogenous nuclease levels to insignificant levels thereby aiding in the liberation of said nucleic acid from sample components.
14. A kit comprising in separate compartments an acid adapted to reduce the pH of a biological sample at or below pH 4.0, and an acid protease adapted to digest cellular materials in a biological sample to release nucleic acid in said sample and to inactivate endogenous nucleases which may be present.
- 45 15. The kit of claim 14, further comprising in a separate compartment a base adapted to raise the pH of the sample following completion of proteolytic digestion.
16. A method of purifying proteases to remove residual RNases comprising the steps of treating a solution of protease with an RNAase adsorbent under conditions in which said adsorbent desorbs RNases in said solution and does not adsorb said protease, and separating said adsorbent from said protease.
- 50 17. The method of claim 16, in which said protease is pepsin.
18. A method for making available a desired nucleic acid contained in a biological sample, comprising the steps of:
 - acidifying said biological sample to a pH at which the activity of endogenous nucleases capable

of degrading the desired nucleic acid(s) are reduced to insignificant levels,
contacting said biological sample with an exogenous acid protease active at said pH,
incubating said biological sample until endogenous nuclease activities are irreversibly reduced to
insignificant levels, and
5 raising the pH of said biological sample to a pH sufficient to render said exogenous protease less
active.

10

15

20

25

30

35

40

45

50

55

16



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number: 0 611 157 A3

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 94300971.2

⑭ Int. Cl. 6: C12P 19/34, C12Q 1/68,
C07H 1/08

⑮ Date of filing: 10.02.94

⑯ Priority: 10.02.93 US 15729

⑰ Inventor: Kacian, Daniel L.
3911 Tambor Road
San Diego, California 92124 (US)
Inventor: Nunomura, Kiyotada
9880 Campus Point Drive
San Diego, California 92121 (US)

⑯ Date of publication of application:
17.08.94 Bulletin 94/33

⑰ Representative: Sexton, Jane Helen et al
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5LX (GB)

⑯ Designated Contracting States:
AT BE CH DE DK ES FR GB IT LI LU NL SE

⑯ Date of deferred publication of search report:
28.12.94 Bulletin 94/52

⑰ Applicant: GEN-PROBE INCORPORATED
9880 Campus Point Drive
San Diego California 92121-1514 (US)

⑯ Method to prepare nucleic acids from a biological sample using low pH and acid protease.

⑯ Method for making available a desired nucleic acid contained in a biological sample, comprising the steps of acidifying said biological sample to a pH at which endogenous nucleases capable of degrading the desired nucleic acid(s) are inactive, contacting said biological sample with an exogenous acid protease active at said pH, incubating said sample until endogenous nuclease activities are reduced to insignificant levels, and raising the pH of the biological sample to a pH sufficient to render the exogenous protease less active.

EP 0 611 157 A3



DOCUMENTS CONSIDERED TO BE RELEVANT			EP 94300971.2
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
A	<u>WO - A - 92/08 807</u> (HRI RESEARCH) * Claims 1-5 * --	1-7,18	C 12 P 19/34 C 12 Q 1/68 C 07 H 1/08
A	<u>EP - A - 0 261 956</u> (E.I. DU PONT DE NEMOURS AND COMPANY) * Claims * --	1,18	
A	<u>WO - A - 91/02 740</u> (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM) * Claims 1-4 * --	1,18	
TECHNICAL FIELDS SEARCHED (Int. Cl. 5)			
C 12 P C 12 Q C 07 H			
<i>The present search report has been drawn up for all claims.</i>			
Place of search VIENNA	Date of compilation of the search 19-05-1994	Examiner WOLF	
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background D : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons S : member of the same patent family, corresponding document			



European Patent
Office

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.
- Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid,
namely claims:
- No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

X LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions.
namely:

1. Claims: 1-15,18 (Methods for making available a nucleic acid, resp. kit)
2. Claims: 16,17 (Method for purifying proteases)

- All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.

- Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid.

namely claims:

- None of the further search fees has been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims.

namely claims: 1-15,18

THIS PAGE BLANK (USPTO)